Small Lymphocytic Lymphoma (SLL)
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Small Lymphocytic Lymphoma (SLL)

What is the definition of Small Lymphocytic Lymphoma (SLL)?
Small lymphocytic lymphoma, also called chronic lymphocytic leukemia, is a slow-growing cancer known as non-Hodgkin lymphoma. Small lymphocytic leukemia involves immature white blood cells called lymphocytes. Lymphocytes are cells that fight infection. While chronic lymphocytic leukemia mainly affects the blood and bone marrow, small lymphocytic lymphoma mainly affects the lymph nodes.
What are the symptoms of Small Lymphocytic Lymphoma (SLL)?
Symptoms of small lymphocytic lymphoma may not appear for many years. Symptoms of small lymphocytic lymphoma may at first be mild and include discomfort and feeling unwell. As small lymphocytic lymphoma slowly progresses, symptoms depend on the location of the tumor and may include fatigue; shortness of breath; swollen, painless lymph nodes; anemia; bleeding; bruising easily; bone pain; fever; night sweats; abdominal swelling; abdominal pain; feeling full after eating a small amount; unexplained weight loss; an enlarged spleen; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Small Lymphocytic Lymphoma (SLL)?
Treatment for small lymphocytic lymphoma depends on the symptoms, the rate at which the cancer is progressing, and an individual’s particular genetic mutations, age, and overall health. Initial treatment for individuals with small lymphocytic lymphoma without symptoms may include watchful waiting. As small lymphocytic lymphoma progresses, treatment may include combination targeted therapies and immunotherapies, such as ibrutinib with or without rituximab, ibrutinib and Obinutuzumab, venetoclax with or without rituximab, venetoclax with Obinutuzumab, and alemtuzumab. Chemotherapy is now rarely used to treat small lymphocytic lymphoma; however, it may still be a treatment option and is usually used in combination with targeted therapies and immunotherapies, such as chlorambucil and Obinutuzumab; fludarabine, cyclophosphamide, and rituximab; ofatumumab and chlorambucil; rituximab and chlorambucil; bendamustine; and corticosteroids, such as dexamethasone and prednisone. Maintenance therapy for patients with small lymphocytic lymphoma who have responded to treatment may include ofatumumab, rituximab, and lenalidomide. Patients with relapsed/refractory small lymphocytic lymphoma may be treated with ibrutinib with or without rituximab or Obinutuzumab, venetoclax with or without rituximab or Obinutuzumab, idelalisib and rituximab or Obinutuzumab, acalabrutinib with or without rituximab or Obinutuzumab, duvelisib, and lenalidomide with or without rituximab. Treatment with allogenic stem cell (bone marrow) transplant from a living donor may provide a cure for patients with small lymphocytic lymphoma but carries a risk of complications. Supportive care for patients with small lymphocytic lymphoma may also include vaccinations to prevent infections. Long-term follow-up for patients with small lymphocytic lymphoma is necessary to monitor disease progression, treatment effects, and to prevent and treat any infections.
Who are the top Small Lymphocytic Lymphoma (SLL) Local Doctors?
Elite in Small Lymphocytic Lymphoma (SLL)
Hematology Oncology | Hematology | Oncology
Elite in Small Lymphocytic Lymphoma (SLL)
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
Experience:
30+ years
Languages Spoken:
English
Offers Telehealth

Brian Hill is a Hematologist Oncology specialist and a Hematologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 30 years. Dr. Hill is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Small Lymphocytic Lymphoma (SLL)
Oncology | Hematology
Elite in Small Lymphocytic Lymphoma (SLL)
Oncology | Hematology

Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD 
Languages Spoken:
English
Offers Telehealth

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Small Lymphocytic Lymphoma (SLL)
Distinguished in Small Lymphocytic Lymphoma (SLL)

Vince Lombardi Cancer Clinic

2900 W Oklahoma Ave, 
Milwaukee, WI 
Languages Spoken:
English, Urdu
Offers Telehealth

Syed Haider is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. Haider is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Chronic Myelogenous Leukemia (CML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Haider is board certified in American Board Of Internal Medicine, Hematology.

What are the latest Small Lymphocytic Lymphoma (SLL) Clinical Trials?
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Summary: The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Summary: Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)